Benazepril

Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy[1][2].

Product Specifications

CAS Number

[86541-75-5]

Product Name Alternative

CGS14824A (free base)

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Angiotensin-converting Enzyme (ACE) ; Apoptosis; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/benazepril.html

Purity

99.85

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1N(CC(O)=O)C2=CC=CC=C2CC[C@@H]1N[C@@H](CCC3=CC=CC=C3)C(OCC)=O

Molecular Formula

C24H28N2O5

Molecular Weight

424.49

Precautions

H302, H312, H332

References & Citations

[1]Hou FF, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006 Jan 12;354 (2) :131-40.|[2]Huang XM, et al. Effects of chronotherapy of benazepril on the diurnal profile of RAAS and clock genes in the kidney of 5/6 nephrectomy rats. J Huazhong Univ Sci Technolog Med Sci. 2013 Jun;33 (3) :368-74.